Table 5.
Association of Heart Failure Index Score With Hospital Stay for HF During 4.4 Years of Follow-Up Among 831 Participants Without a History of HF
| Index Score |
% With Events |
Age-Adjusted HR (95% CI) |
p Value | MV-Adjusted HR (95% CI)* |
p Value | MI Size/Treatment- Adjusted HR (95% CI)† |
p Value | EF-Adjusted HR (95% CI)‡ |
p Value | NT-proBNP–Adjusted HR (95% CI)§ |
p Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0–2 | 3% (9/360) | reference | — | reference | — | reference | — | reference | — | reference | — |
| 3–4 | 7% (17/259) | 2.6 (1.2–5.9) | 0.02 | 2.0 (0.8–5.3) | 0.15 | 1.8 (0.7–4.9) | 0.22 | 1.7 (0.6–4.5) | 0.29 | 2.0 (0.7–5.6) | 0.18 |
| 5–6 | 23% (42/185) | 9.4 (4.6–19.4) | <0.0001 | 6.9 (2.9–16.6) | <0.0001 | 6.8 (2.7–16.6) | <0.0001 | 5.3 (2.1–13.4) | 0.0004 | 4.2 (1.5–11.5) | 0.006 |
| 7–8 | 39% (13/33) | 16.4 (6.9–38.8) | <0.0001 | 11.0 (3.9–30.9) | <0.0001 | 9.5 (3.3–27.4) | <0.0001 | 8.4 (2.9–23.9) | <0.0001 | 5.7 (1.8–17.8) | 0.003 |
*
Adjusted for age, gender, smoking, renal insufficiency, history of hypertension, history of myocardial infarction, history of diabetes, and body mass index.
†
Adjusted for above variables plus: 1) resting wall motion score; 2) prior revascularization; and 3) medication use (beta-blocker, ACE, aspirin, statin).
‡
Adjusted for above variables plus EF.
§
Adjusted for above variables plus log N-terminal part of the pro-B-type natriuretic peptide (NT-proBNP).